Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics (ELVN) reported Q3 2025 results. Operating expenses were $25.1 million, driven by research and development of $18.2 million and general and administrative of $6.9 million. The company recorded a net loss of $20.1 million, or $0.32 per share, compared with a net loss of $23.2 million a year ago.
Cash, cash equivalents and marketable securities totaled $477.6 million as of September 30, 2025, supported by a June underwritten public offering of 9,920,987 shares and pre-funded warrants to purchase 1,780,263 shares, delivering $230.0 million gross proceeds. Net cash used in operating activities for the nine months was $54.5 million. Shares outstanding were 59,347,317 as of October 31, 2025.
The company filed an automatic shelf on August 13, 2025 and added an at-the-market program covering up to $200.0 million of common stock; no sales occurred under the program during the period. Management states existing liquidity will fund planned operating expenses and capital requirements for at least 12 months from issuance.
Enliven Therapeutics (ELVN) reported Q3 2025 results. Operating expenses were $25.1 million, driven by research and development of $18.2 million and general and administrative of $6.9 million. The company recorded a net loss of $20.1 million, or $0.32 per share, compared with a net loss of $23.2 million a year ago.
Cash, cash equivalents and marketable securities totaled $477.6 million as of September 30, 2025, supported by a June underwritten public offering of 9,920,987 shares and pre-funded warrants to purchase 1,780,263 shares, delivering $230.0 million gross proceeds. Net cash used in operating activities for the nine months was $54.5 million. Shares outstanding were 59,347,317 as of October 31, 2025.
The company filed an automatic shelf on August 13, 2025 and added an at-the-market program covering up to $200.0 million of common stock; no sales occurred under the program during the period. Management states existing liquidity will fund planned operating expenses and capital requirements for at least 12 months from issuance.
Enliven Therapeutics (ELVN) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and was issued on November 12, 2025.
The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated.
Enliven Therapeutics (ELVN) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and was issued on November 12, 2025.
The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated.
Enliven Therapeutics (ELVN) reported an insider transaction by its Chief Scientific Officer on Form 4. The filing shows a sale of 12,500 shares of common stock on October 20, 2025 at a weighted average price of $22.082, executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following the sale, the reporting person beneficially owned 915,188 shares, held indirectly through The Lyssikatos Revocable Trust dated 12/15/2011.
The transaction price ranged from $21.285 to $22.36, with full trade details available upon request.
Enliven Therapeutics (ELVN) reported an insider transaction: its President & CEO and Director sold 12,500 shares of Common Stock on 10/17/2025 at a $21.3323 weighted average price. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
The transaction was executed in multiple trades within a price range of $21.1303 to $21.88. Following the sale, the reporting person beneficially owned 902,892 shares, held indirectly by The Kintz & Egan Trust Dated March 30, 2019.
Anish Patel, Chief Operating Officer of Enliven Therapeutics (ELVN), sold 6,667 shares of common stock on 10/07/2025. The sales were executed under a Rule 10b5-1 trading plan adopted on 09/30/2024, and the weighted average sale price was $20.0979. After the reported disposition, the Reporting Person beneficially owns 276,641 shares, held indirectly by The Patel / Dong Family Trust. The Form discloses the trades were executed in multiple transactions at prices ranging from $20.0001 to $20.22, and the filer offers to provide per-trade details on request.
Enliven Therapeutics insider sale by Chief Scientific Officer
Joseph P. Lyssikatos, Enliven Therapeutics' Chief Scientific Officer, reported a sale of 4,000 shares of the company's common stock on 09/26/2025 at a weighted average price of $20.2513 per share. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. After the reported disposition, the reporting person beneficially owns 927,688 shares indirectly through The Lyssikatos Revocable Trust dated 12/15/2011, for which he serves as trustee. The Form 4 was signed by power of attorney on 09/30/2025.
Samuel Kintz, President, CEO and a director of Enliven Therapeutics, Inc. (ELVN), reported a sale of 3,700 shares of the company's common stock on 09/26/2025. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024, and executed in multiple trades at prices ranging from $20.00 to $20.27, with a weighted average price of $20.0615. After the reported disposition, the reporting person beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 is signed by a power of attorney on behalf of the reporting person.
Enliven Therapeutics (ELVN) filing a Form 144 notifies a proposed brokered sale of 4,500 common shares through Jefferies with an aggregate market value of $90,045, planned for 09/29/2025. The shares were acquired as stock options on 08/09/2022 from the company. The filing shows 59,000,000 shares outstanding for the issuer and discloses prior insider sales of 7,500 shares during the past three months with reported gross proceeds totaling roughly $156,197.50. The filer attests there is no undisclosed material adverse information and the transaction will be executed through a broker.
Enliven Therapeutics insider sale reported. Joseph P. Lyssikatos, Chief Scientific Officer and trustee of a revocable trust holding shares, reported a sale of 1,500 shares of Enliven Therapeutics (ELVN) common stock on 09/23/2025 at $20.03 per share. After the reported transaction, the filing shows 931,688 shares beneficially owned indirectly through The Lyssikatos Revocable Trust dated 12/15/2011. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. The Form 4 was submitted by a power of attorney on 09/25/2025.
Samuel Kintz, President, CEO and Director of Enliven Therapeutics (ELVN), reported a sale of 2,800 shares of common stock on 09/23/2025 at a price of $20.03 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. After the transaction, the reporting person beneficially owns 919,092 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 was signed by Ben Hohl by power of attorney on 09/25/2025.